PharmD Info

A forum for Indian Pharmacy Professionals

Discuss and Learn about ADR monitoring techniques, ADR reporting forms, Indian ADR centers, ADR Mobile application, ADR management and etc.
  • User avatar
#1263
Dermatology
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Approved March 2016

Family Medicine
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016

Hematology
Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring; For the treatment of hemophilia B, Approved March 2016

Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Hepatology (Liver, Pancreatic, Gall Bladder)
Defitelio (defibrotide sodium); Jazz Pharmaceuticals; For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT, Approved March 2016

Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Immunology
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016

Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis, Approved March 2016

Infections and Infectious Diseases
Anthim (obiltoxaximab); Elusys Therapeutics; For the treatment of inhalational anthrax , Approved March 2016

Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016

Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Nephrology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016

Neurology
Briviact (brivaracetam); UCB; For the treatment of partial onset seizures related to epilepsy, Approved February 2016

Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease, Approved April 2016

Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016

Oncology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Pediatrics/Neonatology
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016

Pulmonary/Respiratory Diseases
Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca; For the treatment of chronic obstructive pulmonary disease, Approved April 2016

Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe asthma, Approved March 2016

Virtual Requirement Drive for Clinical Pharmacist […]

Greetings from Sree Dattha Institute of Pharmacy […]

Required Manager Clinical Pharmacy - Venkateswar H[…]

To, The HR Manager, MGM new Bombay hospital Navi M[…]

PharmD Info - Highlights